



Vigilancia de la Parálisis Flácida Aguda en las Américas

Vol. 39, No. 35-36

Semana que termina el 7 de septiembre del 2024

Tabla No.1
Casos PFA esperados y reportados, 2024

| Sub región | País | Población <15 años* | Casos PFA esperados | Casos PFA reportados 2024/36 |
|--------------|------|---------------------|---------------------|------------------------------|
| AND | BOL | 3,697,500 | 37 | 20 |
| | COL | 10,721,183 | 107 | 77 |
| | ECU | 4,435,185 | 44 | 41 |
| | PER | 8,202,156 | 82 | 62 |
| | VEN | 7,251,084 | 73 | 30 |
| BRA | BRA | 41,689,815 | 417 | 269 |
| CAP | CRI | 964,386 | 10 | 6 |
| | GTM | 5,812,199 | 58 | 40 |
| | HND | 3,314,961 | 33 | 31 |
| | NIC | 1,989,004 | 20 | 18 |
| | PAN | 1,124,149 | 11 | 8 |
| | SLV | 1,572,260 | 16 | 25 |
| CAR | CAR | 1,798,300 | 18 | 4 |
| LAC | CUB | 1,679,242 | 17 | 5 |
| | DOM | 3,037,290 | 30 | 19 |
| | HTI | 3,671,700 | 37 | 7 |
| MEX | MEX | 32,073,369 | 321 | 515 |
| NOA | CAN | 6,005,606 | 60 | 5 |
| | USA | 59,843,692 | 598 | NR |
| SOC | ARG | 9,872,172 | 99 | 33 |
| | CHL | 3,353,323 | 34 | 31 |
| | PRY | 1,980,901 | 20 | 24 |
| | URY | 619,507 | 6 | 1 |
| Total | | 214,708,984 | 2148 | 1271 |

Tabla No.2
Casos PFA bajo investigación (Todas las edades)

| Sub región | País | Total 2023 | Acum. 2024 | Semana | | | | | | | | | | | |
|--------------|------|------------|------------|------------|-----------|-----------|-----------|-----------|-----------|----------|----------|----------|------------|------------|--|
| | | | | 1-28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | | | |
| AND | BOL | 0 | 23 | 22 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | COL | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
| | ECU | 0 | 4 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | ... | |
| | PER | 10 | 27 | 15 | 3 | 1 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 0 | |
| | VEN | 0 | 23 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | ... | ... | ... | ... | |
| BRA | BRA | 0 | 88 | 60 | 7 | 4 | 6 | 3 | 4 | 3 | 1 | 0 | 0 | | |
| CAP | CRI | 0 | 1 | 1 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| | GTM | 26 | 40 | 40 | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| | HND | 0 | 16 | 9 | 2 | 3 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| | NIC | 0 | 6 | 2 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | ... | ... | ... | |
| | PAN | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ... | |
| | SLV | 0 | 9 | 6 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | ... | ... | |
| CAR | CAR | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| LAC | CUB | 3 | 5 | 5 | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| | DOM | 2 | 19 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ... | |
| | HTI | 12 | 9 | 8 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| MEX | MEX | 0 | 35 | 13 | 2 | 2 | 3 | 0 | 3 | 6 | 5 | 1 | ... | | |
| NOA | CAN | 0 | 0 | 0 | 0 | 0 | 0 | ... | ... | ... | ... | ... | ... | ... | |
| | USA | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| SOC | ARG | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ... | |
| | CHL | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | PRY | 0 | 5 | 0 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| | URY | 0 | 1 | 1 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| Total | | 53 | 302 | 221 | 14 | 14 | 15 | 10 | 14 | 8 | 5 | 1 | ... | ... | |

*ONU, Perspectivas de población mundial 2024, edición en línea. NR - No Reporta ... - Sin datos

Tabla No.3 Casos de polio confirmados y compatibles, e indicadores de vigilancia de PFA, 2024 y 2023

| Sub región | País | Polio 2024 | | Casos PFA e indicadores, últimas 52 semanas (2023/37 - 2024/36) | | | | | Polio 2023 | | Casos PFA e indicadores, 2023 (2023/1 - 2023/52) | | | | |
|--------------|------|------------|------------|---|-------------|-----------------|---------------------|--------------------|------------|------------|--|-------------|-----------------|---------------------|--------------------|
| | | Confirmado | Compatible | Casos | Tasa | % Inv. <48 hrs. | % muestra adecuada* | % unid. notifican. | Confirmado | Compatible | Casos | Tasa | % Inv. <48 hrs. | % muestra adecuada* | % unid. notifican. |
| AND | BOL | 0 | 0 | 30 | 0.79 | 90 | 80 | ... | 0 | 0 | 31 | 0.82 | 90 | 87 | ... |
| | COL | 0 | 0 | 114 | 1.04 | 80 | 94 | 99 | 0 | 0 | 160 | 1.45 | 88 | 88 | 98 |
| | ECU | 0 | 0 | 57 | 1.24 | 65 | 81 | ... | 0 | 0 | 62 | 1.35 | 74 | 71 | ... |
| | PER | 0 | 0 | 99 | 1.12 | 87 | 72 | 1 | 0 | 0 | 117 | 1.33 | 89 | 64 | 5 |
| | VEN | 0 | 0 | 62 | 0.80 | 98 | 89 | ... | 0 | 0 | 137 | 1.78 | 100 | 93 | ... |
| BRA | BRA | 0 | 0 | 404 | 0.93 | 98 | 66 | ... | 0 | 1 | 541 | 1.25 | 99 | 69 | ... |
| CAP | CRI | 0 | 0 | 16 | 1.55 | 100 | 88 | 98 | 0 | 0 | 26 | 2.52 | 100 | 88 | 99 |
| | GTM | 0 | 0 | 61 | 1.05 | 100 | 23 | 69 | 0 | 0 | 90 | 1.56 | 100 | 17 | 76 |
| | HND | 0 | 0 | 49 | 1.48 | 82 | 90 | 92 | 0 | 0 | 43 | 1.37 | 74 | 86 | 94 |
| | NIC | 0 | 0 | 21 | 1.02 | 90 | 86 | ... | 0 | 0 | 39 | 1.89 | 92 | 77 | ... |
| | PAN | 0 | 0 | 12 | 1.04 | 92 | 67 | 89 | 0 | 0 | 10 | 0.87 | 70 | 100 | 90 |
| | SLV | 0 | 0 | 42 | 2.64 | 90 | 100 | 80 | 0 | 0 | 54 | 3.39 | 93 | 94 | 63 |
| CAR | CAR | 0 | 0 | 4 | 0.22 | 0 | 50 | 42 | 0 | 0 | 5 | 0.28 | 60 | 20 | 53 |
| LAC | CUB | 0 | 0 | 17 | 0.98 | 94 | 100 | 100 | 0 | 0 | 30 | 1.72 | 97 | 97 | 100 |
| | DOM | 0 | 0 | 21 | 0.69 | 33 | 38 | ... | 0 | 0 | 11 | 0.36 | 55 | 45 | ... |
| | HTI | 0 | 0 | 15 | 0.40 | 93 | 60 | 75 | 0 | 0 | 11 | 0.30 | 100 | 27 | 80 |
| MEX | MEX | 0 | 0 | 719 | 2.24 | 99 | 83 | 95 | 0 | 0 | 617 | 2.00 | 100 | 86 | 95 |
| NOA | CAN | 0 | 0 | 10 | 0.17 | ... | 20 | ... | 0 | 0 | 28 | 0.47 | ... | 18 | ... |
| | USA | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| SOC | ARG | 0 | 0 | 82 | 0.79 | 10 | 76 | ... | 0 | 0 | 140 | 1.35 | 10 | 70 | 0 |
| | CHL | 0 | 0 | 56 | 1.57 | 82 | 63 | 74 | 0 | 0 | 87 | 2.44 | 83 | 55 | 84 |
| | PRY | 0 | 0 | 34 | 1.72 | 97 | 91 | 98 | 0 | 0 | 31 | 1.57 | 97 | 81 | 96 |
| | URY | 0 | 0 | 3 | 0.47 | 100 | ... | ... | 0 | 0 | 3 | 0.47 | 67 | ... | ... |
| Total | | 0 | 0 | 1928 | 1.24 | 89 | 76 | ... | 0 | 1 | 2273 | 1.41 | 89 | 75 | ... |

+ Tomado dentro de los primeros 14 días del inicio de parálisis ... - Sin datos NR - No reportando CAR incluye informes de países miembros de CARPHA

Sólo se incluyen datos de casos de PFA en menores de 15 años en tablas 1 y 3

El boletín de vigilancia de la poliomielitis se encuentra en: <https://www.paho.org/es/boletin-polio>



Tabla No.1
Resultados e indicadores de aislamiento viral, últimas 52 semanas
Semanas epidemiológicas 2023/37 - 2024/36

| Lab. | País | Número de muestras de casos de PFA | Prueba de aislamiento viral | | | | | | | | | | % muestras positivas de NPEV | Tiempo para el resultado de aislamiento | | |
|---------------------|------|------------------------------------|-----------------------------|-------------------|-------------------|------------------|-------------------|-----------|-------------|----------|------------|----------|------------------------------|---|---|---------------------------|
| | | | Pendiente de resultados | | | Con resultados | | | | | | | | Total muestras con resultado | Total con fecha de recepción y de resultado | % con resultado ≤ 14 días |
| | | | Aún no en lab. | Recibido ≤14 días | Recibido >14 días | Sólo polio virus | Poliovirus y NPEV | Sólo NPEV | Negativo | Otros | Inadecuado | | | | | |
| CAR | HND | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | |
| | HTI | 14 | 0 | 0 | 2 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 12 | 12 | 42 | |
| | JAM | 14 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | NIC | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 4 | 100 | |
| | PAN | 21 | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 15 | 0 | 0 | 6 | 16 | 100 | |
| | TTO | 12 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 9 | 78 | |
| CDC | BOL | 41 | 24 | 0 | 2 | 0 | 0 | 3 | 12 | 0 | 0 | 20 | 15 | 15 | 93 | |
| | CRI | 15 | 5 | 0 | 2 | 0 | 0 | 2 | 6 | 0 | 0 | 25 | 8 | 8 | 13 | |
| | DOM | 16 | 1 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 0 | 15 | 15 | 100 | |
| | GTM | 61 | 51 | 0 | 1 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 9 | 9 | 78 | |
| | HND | 21 | 3 | 0 | 0 | 0 | 0 | 1 | 17 | 0 | 0 | 6 | 18 | 18 | 100 | |
| | PRY | 34 | 10 | 0 | 0 | 0 | 0 | 3 | 21 | 0 | 0 | 13 | 24 | 24 | 92 | |
| | SLV | 42 | 0 | 0 | 2 | 0 | 0 | 0 | 40 | 0 | 0 | 0 | 40 | 40 | 0 | |
| FIO | BRA | 289 | 8 | 0 | 23 | 4 | 0 | 12 | 242 | 0 | 0 | 6 | 258 | 257 | 72 | |
| | PER | 60 | 0 | 0 | 1 | 0 | 0 | 0 | 59 | 0 | 0 | 0 | 59 | 59 | 90 | |
| IEC | BRA | 42 | 1 | 0 | 1 | 0 | 0 | 0 | 40 | 0 | 0 | 0 | 40 | 38 | 82 | |
| INDRE | MEX | 626 | 0 | 19 | 10 | 0 | 0 | 51 | 546 | 0 | 0 | 9 | 597 | 596 | 99 | |
| INH | VEN | 60 | 10 | 0 | 1 | 0 | 0 | 1 | 48 | 0 | 0 | 2 | 49 | 49 | 80 | |
| INS | COL | 114 | 0 | 1 | 0 | 0 | 0 | 9 | 104 | 0 | 0 | 8 | 113 | 113 | 97 | |
| INS | ECU | 53 | 1 | 0 | 1 | 0 | 0 | 1 | 50 | 0 | 0 | 2 | 51 | 51 | 63 | |
| IPK | BRA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | |
| | CUB | 17 | 4 | 0 | 4 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 9 | 9 | 89 | |
| ISP | PER | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 50 | |
| | CHL | 40 | 0 | 0 | 0 | 0 | 0 | 1 | 39 | 0 | 0 | 3 | 40 | 40 | 80 | |
| MAL | ARG | 79 | 0 | 0 | 0 | 0 | 0 | 6 | 73 | 0 | 0 | 8 | 79 | 78 | 83 | |
| (sin nombre de lab) | ARG | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 100 | |
| | BOL | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | CAN | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | |
| | ECU | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 100 | |
| | HND | 15 | 13 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 1 | 0 | |
| | HTI | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | PER | 18 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| VEN | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | |
| Total | | 1723 | 171 | 22 | 34 | 2 | 0 | 92 | 1402 | 0 | 0 | 6 | 1496 | 1484 | 85 | |

... Sin datos Sólo se incluyen muestras de heces de casos de PFA en menores de 15 años

Tabla No.2
Estado de pruebas de diferenciación intratípica (ITD) para muestras con aislamiento de poliovirus, últimas 52 semanas
Semanas epidemiológicas 2023/37 - 2024/36

| Lab. | País | Número de poliovirus aislados | Resultado de diferenciación intratípica de poliovirus | | | | | | | | | Indicadores ITD | | | | | |
|--------------|------|-------------------------------|---|----------|----------|----------|----------|----------|----------|----------|----------|----------------------------|--------------------------------------|---|--|---|---|
| | | | Sabin | | | VDPV | | | Salvaje | | | Pendiente de resultado ITD | Número de muestras con resultado ITD | Resultado ITD con fechas de recepción o detección y resultado | % con resultado ITD ≤ 7 días de la recepción o detección | % con resultado ITD ≤ 45 días del inicio de parálisis | % con resultado ITD ≤ 60 días del inicio de parálisis |
| | | | P1 | P2 | P3 | P1 | P2 | P3 | P1 | P2 | P3 | | | | | | |
| FIO | BRA | 4 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 75 | 75 | 100 |
| Total | | 4 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 75 | 75 | 100 |